These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 16897706

  • 1. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
    Outeiro TF, Giorgini F.
    Biotechnol J; 2006 Mar; 1(3):258-69. PubMed ID: 16897706
    [Abstract] [Full Text] [Related]

  • 2. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB, Geyer R, Hughes TR, Boone C.
    Prog Cell Cycle Res; 2003 Mar; 5():159-66. PubMed ID: 14593709
    [Abstract] [Full Text] [Related]

  • 3. Yeast as a tool to uncover the cellular targets of drugs.
    Sturgeon CM, Kemmer D, Anderson HJ, Roberge M.
    Biotechnol J; 2006 Mar; 1(3):289-98. PubMed ID: 16897709
    [Abstract] [Full Text] [Related]

  • 4. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration.
    Tenreiro S, Munder MC, Alberti S, Outeiro TF.
    J Neurochem; 2013 Nov; 127(4):438-52. PubMed ID: 23600759
    [Abstract] [Full Text] [Related]

  • 5. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease?
    Gitler AD.
    Neurosignals; 2008 Nov; 16(1):52-62. PubMed ID: 18097160
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Yeast and drug discovery.
    Hughes TR.
    Funct Integr Genomics; 2002 Sep; 2(4-5):199-211. PubMed ID: 12192593
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Simple is good: yeast models of neurodegeneration.
    Tenreiro S, Outeiro TF.
    FEMS Yeast Res; 2010 Dec; 10(8):970-9. PubMed ID: 20579105
    [Abstract] [Full Text] [Related]

  • 11. Yeast unfolds the road map toward alpha-synuclein-induced cell death.
    Franssens V, Boelen E, Anandhakumar J, Vanhelmont T, Büttner S, Winderickx J.
    Cell Death Differ; 2010 May; 17(5):746-53. PubMed ID: 20019751
    [Abstract] [Full Text] [Related]

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R, Merchant KM, Ryan T.
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [Abstract] [Full Text] [Related]

  • 19. Using budding yeast to screen for anti-prion drugs.
    Tribouillard D, Bach S, Gug F, Desban N, Beringue V, Andrieu T, Dormont D, Galons H, Laude H, Vilette D, Blondel M.
    Biotechnol J; 2006 Jan; 1(1):58-67. PubMed ID: 16892225
    [Abstract] [Full Text] [Related]

  • 20. Caenorhabditis elegans: a versatile platform for drug discovery.
    Artal-Sanz M, de Jong L, Tavernarakis N.
    Biotechnol J; 2006 Dec; 1(12):1405-18. PubMed ID: 17109493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.